Vulvar Herpes Simplex Infection – A Comprehensive Medical Guide
Overview
Vulvar herpes simplex infection is a sexually transmitted infection (STI) caused by the herpes simplex virus (HSV) that involves the external female genitalia (the vulva). The condition is most often due to HSV‑1 or HSV‑2. While both viruses can affect the vulva, HSV‑2 is traditionally associated with genital disease, whereas HSV‑1 is increasingly responsible for first‑time genital outbreaks because of oral‑genital contact.
The infection is characterized by recurrent painful blisters or ulcers that may be accompanied by systemic symptoms during the initial episode. It is a chronic condition—once infected, the virus remains latent in nerve ganglia and can reactivate periodically.
Who it affects
- Sexually active women of any age, though the highest incidence is in those aged 15–35 years.
- People with a history of other STIs, weakened immune systems (e.g., HIV infection, immunosuppressive therapy), or who use inhaled or injectable drugs.
- Pregnant women – genital HSV can be transmitted to the neonate during delivery.
Prevalence
- According to the CDC, an estimated 12% of U.S. adults (≈ 30 million) have genital HSV‑2 infection.
- Globally, the World Health Organization (WHO) estimates that 491 million people (13% of the world’s population) live with HSV‑2, with a slightly higher prevalence among women.
Symptoms
The clinical picture varies between the primary (first) outbreak and recurrent episodes.
Primary outbreak (usually within 2 weeks of exposure)
- Painful vesicles or blisters on the vulva, labia majora/minora, or perineal area. Blisters break open, forming shallow ulcers.
- Systemic symptoms – fever, malaise, headache, muscle aches, and swollen lymph nodes in the groin.
- Itching or burning sensation before lesions appear (prodrome).
- Urinary discomfort – pain or burning during urination if lesions are near the urethral meatus.
Recurrent outbreaks
- Lesions are typically fewer in number, smaller, and heal faster (usually 5‑10 days).
- Prodromal tingling, itching, or burning may precede lesions by a few hours.
- Some women experience asymptomatic viral shedding – the virus is present on the skin without visible lesions, which can still transmit infection.
Less common symptoms
- Vulvar ulceration that mimics other conditions (e.g., syphilis, chancroid).
- Secondary bacterial infection of lesions – characterized by increased redness, swelling, pus, and foul odor.
Causes and Risk Factors
Viral Etiology
HSV is a DNA virus in the Herpesviridae family. Two types are relevant:
- HSV‑1 – traditionally oral herpes; now responsible for up to 50% of first genital infections in some Western countries.
- HSV‑2 – the classic cause of genital herpes, with a higher tendency for recurrent genital outbreaks.
Transmission
- Direct skin‑to‑skin contact with an infected area or mucous membrane during vaginal, oral, or anal sex.
- Contact with infected secretions (e.g., vaginal fluid, semen) from an asymptomatic partner during viral shedding.
- Rarely, autoinoculation (self‑transfer) from oral HSV‑1 to the genital area.
Risk Factors
- Multiple or new sexual partners.
- Inconsistent condom use – condoms reduce but do not eliminate risk because HSV can affect uncovered skin.
- Co‑existing STIs (e.g., chlamydia, gonorrhea) that breach mucosal barriers.
- Immunosuppression – HIV infection, organ transplantation, chronic corticosteroid use.
- Pregnancy – hormonal changes can increase susceptibility to reactivation.
Diagnosis
Accurate diagnosis relies on a combination of clinical assessment and laboratory testing.
Clinical Evaluation
- Visual inspection of characteristic vesicles/ulcers.
- Documentation of prodromal symptoms and lesion distribution.
- History taking focused on sexual exposure, prior outbreaks, and immune status.
Laboratory Tests
- Polymerase‑Chain Reaction (PCR) assay – the most sensitive test; can be performed on swab specimens from lesions or on blood for viral DNA.
- Viral culture – less sensitive than PCR; useful when immediate results are needed.
- Type‑specific serology – detects HSV‑1 and HSV‑2 IgG antibodies; helpful for asymptomatic patients or when lesions are absent.
- Tzanck smear – rapid, low‑sensitivity cytologic test showing multinucleated giant cells; rarely used in modern practice.
Guidelines from the CDC recommend PCR or culture for any active lesion, especially in pregnant women or immunocompromised patients.
Treatment Options
While there is no cure, antiviral therapy can shorten outbreaks, reduce symptom severity, and lower transmission risk.
Antiviral Medications
| Drug | Typical Dose (Adults) | Duration |
|---|---|---|
| Acyclovir | 400 mg orally 5×/day | 7‑10 days (primary); 5‑7 days (recurrence) |
| Valacyclovir | 1 g orally BID | 7‑10 days (primary); 1 g once daily (suppressive) |
| Famciclovir | 250 mg orally TID | 7‑10 days (primary); 250 mg BID (suppressive) |
For pregnant women, acyclovir is considered safe (Category B) and is the drug of choice.
Suppressive Therapy
- Daily antiviral (e.g., valacyclovir 500 mg once daily) in patients with ≥4 outbreaks per year or those who wish to minimize transmission to a partner.
- Reduces recurrence frequency by up to 70% and shortens viral shedding periods (CDC, 2023).
Adjunctive Measures
- Pain control – acetaminophen or ibuprofen; topical lidocaine 5% gel for local relief.
- Wound care – keep lesions clean and dry; avoid tight clothing; use sitz baths for comfort.
- Education – counseling about the chronic nature and transmission risk.
When Procedures May Be Needed
- Severe secondary bacterial infection – requires oral antibiotics (e.g., cephalexin) and possible incision & drainage.
- Persistent ulceration beyond 2 weeks – consider biopsy to exclude malignancy, especially in immunocompromised patients.
Living with Vulvar Herpes Simplex Infection
Managing a chronic STI involves both medical and lifestyle strategies.
Daily Management Tips
- Track outbreaks – use a diary or a mobile app to note prodrome, lesion appearance, and triggers.
- Prompt treatment – start antiviral therapy at the first sign of tingling or redness; earlier treatment shortens the episode.
- Maintain genital hygiene – gently wash with mild, fragrance‑free soap; pat dry.
- Avoid irritants – skip scented wipes, tight synthetic underwear, and harsh detergents.
- Stress reduction – stress is a known trigger; practice relaxation techniques (yoga, meditation).
- Safe sex practices – disclose status to partners, use latex condoms, and consider antiviral suppressive therapy.
- Vaccinations – stay up to date on HPV and Hepatitis B vaccines, which protect against other genital infections.
Psychosocial Support
Feelings of shame or anxiety are common. Seek counseling, join support groups (e.g., Herpes Support Group), and discuss concerns with a trusted healthcare provider.
Prevention
While no method guarantees absolute protection, risk can be markedly reduced.
- Consistent condom use – correct use lowers transmission by ~30‑50% (CDC, 2022).
- Dental dams for oral–genital contact.
- Antiviral suppressive therapy for the infected partner.
- Limiting the number of sexual partners and ensuring partners are screened for STIs.
- Avoid sexual activity during outbreaks or prodrome – lesions are most infectious then.
- Regular STI testing – at least annually, more often with new or multiple partners.
Complications
Although many cases are mild, untreated or severe infections can lead to complications.
- Neonatal herpes – vertical transmission during vaginal delivery can cause severe disease in newborns; cesarean delivery is recommended if active lesions are present at labor onset.
- Secondary bacterial infection – can progress to cellulitis or, rarely, necrotizing fasciitis.
- Psychological impact – depression, anxiety, and sexual dysfunction.
- Increased HIV acquisition risk – genital ulcers facilitate HIV entry; studies show a 2‑3‑fold increased risk.
- Chronic pain syndromes – post‑herpetic neuralgia is rare in genital HSV but can occur, especially in immunocompromised patients.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Severe, worsening pain or swelling of the vulva that spreads rapidly.
- Fever > 101 °F (38.3 °C) accompanied by stiff neck, headache, or confusion – signs of possible systemic infection or meningitis.
- Difficulty urinating or inability to pass urine despite intense pain.
- Rapidly spreading redness (erythema) with warm, tender skin – could indicate necrotizing fasciitis.
- Signs of an allergic reaction to medication (hives, swelling of face or throat, trouble breathing).
- Pregnant woman with active genital lesions approaching labor – immediate obstetric evaluation is essential.
References
- Centers for Disease Control and Prevention. Genital Herpes – CDC Fact Sheet. Updated 2023.
- World Health Organization. Herpes Simplex Virus Fact Sheet. 2022.
- Mayo Clinic. Genital Herpes. Reviewed 2024.
- Cleveland Clinic. Genital Herpes. Accessed April 2026.
- National Institutes of Health. Management of Genital Herpes in Pregnancy. J Obstet Gynecol Neonatal Med. 2021.
- American College of Obstetricians and Gynecologists. Practice Bulletin No. 227: Genital Herpes in Pregnancy. 2020.